Esters of the ophyllinylacetic acid

A compound of the formula (II):

• ##STR6## wherein R is hydrogen or methyl and n is a number from 1 to 4.

A pharmaceutical composition in oral or parenteral administration form useful for treating adverse hyperlipidemic states in humans which comprises a therapeutically effective amount of a compound of the formula (I):

• ##STR7## wherein R is hydrogen or methyl, n is a number from 1 to 4 and `Acyl` is nicotinoyl, 3-methylpyrazole-5-carboyl, 3-methylisoxazolyl-5-carboyl, 5-n-butylpyridin-2-carboyl, 2-(4-chlorophenoxy)-2-methyl-propionyl, 2-acetoxybenzoyl or theophyllinyl-7-acetyl, in combination with a pharmaceutically acceptable carrier.

A pharmaceutical composition in oral or parenteral administration form useful for treating adverse hyperlipidemic states in humans which comprises a therapeutically effective amount of a compound of the formula (II):

• ##STR8## wherein R is hydrogen or methyl and n is a number from 1 to 4, in combination with a pharmaceutically acceptable carrier.

A method of treating adverse hyperlipidemic states in humans which comprises orally or parenterally administering a therapeutically effective amount of a compound of the formula (I):

• ##STR9## wherein R is hydrogen or methyl;
• n is a number from 1 to 4 and `Acyl` is nicotinoyl, 3-methylpyrazole-5-carboyl, 3-methylisoxazolyl-5-carboyl, 5-n-butylpyridin-2-carboyl, 2-(4-chlorophenoxy)-2-methyl-propionyl, 2-acetoxybenzoyl or theophyllinyl-7-acetyl;
• in combination with a pharmaceutically acceptable carrier.

A method of treating adverse hyperlipidemic states in humans which comprises orally or parenterally administering a therapeutically effective amount of a compound of the formula (II):

• ##STR10## wherein R is hydrogen or methyl and n is a number from 1 to 4, in combination with a pharmaceutically acceptable carrier.